FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256554685> ?p ?o ?g. }

• W4256554685 endingPage "S149" @default.
• W4256554685 startingPage "S149" @default.
• W4256554685 abstract "Stereotactic ablative radiotherapy (SabR) is an increasingly utilized treatment modality for liver metastases, but limited data are available on outcomes and toxicity from single fraction treatment. We report long term outcomes from a Phase I dose-escalation study to determine the maximum tolerated dose of single-fraction liver SabR pooled with our subsequent single institutional experience with patients treated post-protocol at the highest dose level (40 Gy) from the Phase I study. Patients with liver metastases from solid tumors located outside of the central liver zone, defined as a 2-cm expansion around the course of the portal vein to its bifurcation in the liver, were treated with single-fraction SabR on a Phase I dose escalation trial. At least 700 cc of normal liver had to receive <9.1 Gy. Seven patients were enrolled to the first dose level (prescription dose of 35 Gy). Dose was then escalated to 40 Gy in a single fraction, and seven more patients were treated. An additional 19 patients with liver metastases from solid tumors were subsequently treated to 40 Gy in a single fraction post-protocol. Treatment plan was defined by multidisciplinary team in all cases. Patients were followed for toxicity and underwent serial imaging to assess for local control. Median imaging follow up for the combined cohort (n = 33, 39 lesions) was 21.3 months; 38.9 months for protocol patients and 12.8 months for subsequent patients. Fourteen patients with 17 liver metastases were treated on protocol, and subsequently 19 additional patients with 22 liver metastases were treated to 40 Gy. All patients had confirmed metastatic disease, and 36.3% had other non-hepatic sites of metastatic disease at time of treatment. Median lesion size was 2.1 cm (range 0.5-5.0 cm). The majority of patients had colorectal (45.5%) or renal (21.1%) malignancies. As previously reported, there were no dose-limiting toxicities observed at either dose level for protocol patients, and only three Grade 2 toxicities (abdominal pain, nausea/vomiting, alkaline phosphatase elevation) were observed in the entire cohort, with no Grade ≥ 3 toxicities attributable to treatment. There were two local failures (5.1% crude rate of failure); one marginal failure in the protocol group in the 40 Gy cohort (73.5 months post-treatment), and one in-field failure in the subsequent group (14.5 months post-treatment); both patients’ lesions were colorectal histology. Four-year actuarial local control of irradiated lesions in the entire cohort was 96.2%; 100% in the protocol group and 91% in the subsequent patients, respectively. Two- and four-year overall survival for all treated patients was 80% and 45.7%, respectively. For selected patients with liver metastases, single-fraction SabR at doses of 35 and 40 Gy was safe and well-tolerated, and shows excellent local control with long term follow-up; results in subsequent patients treated with single-fraction SabR doses of 40 Gy confirm our earlier results." @default.
• W4256554685 created "2022-05-12" @default.
• W4256554685 creator A5008064441 @default.
• W4256554685 creator A5009289831 @default.
• W4256554685 creator A5016633692 @default.
• W4256554685 creator A5017716856 @default.
• W4256554685 creator A5033395766 @default.
• W4256554685 creator A5034674540 @default.
• W4256554685 creator A5036054930 @default.
• W4256554685 creator A5050927445 @default.
• W4256554685 creator A5060529206 @default.
• W4256554685 creator A5064657246 @default.
• W4256554685 creator A5067568215 @default.
• W4256554685 creator A5085283718 @default.
• W4256554685 date "2020-11-01" @default.
• W4256554685 modified "2023-09-26" @default.
• W4256554685 title "Long Term Results of a Phase I Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases" @default.
• W4256554685 doi "https://doi.org/10.1016/j.ijrobp.2020.07.899" @default.
• W4256554685 hasPublicationYear "2020" @default.
• W4256554685 type Work @default.
• W4256554685 citedByCount "2" @default.
• W4256554685 countsByYear W42565546852021 @default.
• W4256554685 crossrefType "journal-article" @default.
• W4256554685 hasAuthorship W4256554685A5008064441 @default.
• W4256554685 hasAuthorship W4256554685A5009289831 @default.
• W4256554685 hasAuthorship W4256554685A5016633692 @default.
• W4256554685 hasAuthorship W4256554685A5017716856 @default.
• W4256554685 hasAuthorship W4256554685A5033395766 @default.
• W4256554685 hasAuthorship W4256554685A5034674540 @default.
• W4256554685 hasAuthorship W4256554685A5036054930 @default.
• W4256554685 hasAuthorship W4256554685A5050927445 @default.
• W4256554685 hasAuthorship W4256554685A5060529206 @default.
• W4256554685 hasAuthorship W4256554685A5064657246 @default.
• W4256554685 hasAuthorship W4256554685A5067568215 @default.
• W4256554685 hasAuthorship W4256554685A5085283718 @default.
• W4256554685 hasConcept C106159729 @default.
• W4256554685 hasConcept C126322002 @default.
• W4256554685 hasConcept C126838900 @default.
• W4256554685 hasConcept C155806632 @default.
• W4256554685 hasConcept C162324750 @default.
• W4256554685 hasConcept C187625094 @default.
• W4256554685 hasConcept C2989005 @default.
• W4256554685 hasConcept C509974204 @default.
• W4256554685 hasConcept C71924100 @default.
• W4256554685 hasConcept C72563966 @default.
• W4256554685 hasConcept C85393063 @default.
• W4256554685 hasConcept C91602232 @default.
• W4256554685 hasConceptScore W4256554685C106159729 @default.
• W4256554685 hasConceptScore W4256554685C126322002 @default.
• W4256554685 hasConceptScore W4256554685C126838900 @default.
• W4256554685 hasConceptScore W4256554685C155806632 @default.
• W4256554685 hasConceptScore W4256554685C162324750 @default.
• W4256554685 hasConceptScore W4256554685C187625094 @default.
• W4256554685 hasConceptScore W4256554685C2989005 @default.
• W4256554685 hasConceptScore W4256554685C509974204 @default.
• W4256554685 hasConceptScore W4256554685C71924100 @default.
• W4256554685 hasConceptScore W4256554685C72563966 @default.
• W4256554685 hasConceptScore W4256554685C85393063 @default.
• W4256554685 hasConceptScore W4256554685C91602232 @default.
• W4256554685 hasIssue "3" @default.
• W4256554685 hasLocation W42565546851 @default.
• W4256554685 hasOpenAccess W4256554685 @default.
• W4256554685 hasPrimaryLocation W42565546851 @default.
• W4256554685 hasRelatedWork W1919433043 @default.
• W4256554685 hasRelatedWork W2040306711 @default.
• W4256554685 hasRelatedWork W2085251456 @default.
• W4256554685 hasRelatedWork W2255894970 @default.
• W4256554685 hasRelatedWork W2384708512 @default.
• W4256554685 hasRelatedWork W2525056901 @default.
• W4256554685 hasRelatedWork W2603773853 @default.
• W4256554685 hasRelatedWork W2897723160 @default.
• W4256554685 hasRelatedWork W3167035089 @default.
• W4256554685 hasRelatedWork W4307146680 @default.
• W4256554685 hasVolume "108" @default.
• W4256554685 isParatext "false" @default.
• W4256554685 isRetracted "false" @default.
• W4256554685 workType "article" @default.